Home > Signaling Pathways>Metabolism>Decarboxylase>Benserazide hydrochloride (Serazide; Ro 4-4602)
Benserazide hydrochloride (Serazide; Ro 4-4602)

This product is for research use only, not for human use. We do not sell to patients.

Benserazide hydrochloride (Serazide; Ro 4-4602)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
10g$400Check With Us
25g$750Check With Us
50g$1125Check With Us

Cat #: V32716 CAS #: 14919-77-8 Purity ≥ 99%

Description: Benserazide HCl (Ro-44602; Serazide; Ro 4-4602), the hydrochloride salt of Benserazide, is a carbohydrazide-based, peripherally acting inhibitor of aromatic L-amino acid decarboxylase/AADC or DOPA decarboxylase and a medication used in combination with levodopa (madopar) to treat Parkinson's disease, parkinsonism, and restless leg syndrome.

References: Shen H, et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med. 2003 Mar;199(3):149-59.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)293.70
Molecular FormulaC10H16ClN3O5
CAS No.14919-77-8
SynonymsBenserazide hydrochloride; Serazide; Ro 4-4602
ProtocolIn VitroBenserazide hydrochloride (BH) and Levodopa (LD) individually and in combination (Benserazide hydrochloride + LD) (25 μM; 0 hour, 12 hours, 24 hours and 168 hours; SH-SY5Y) treatment inhibit protein aggregation and have the ability to minimise the amyloid-induced cytotoxicity in human neuroblastoma cell line. Benserazide hydrochloride and LD both can act as efficient inhibitors of the formation of cytotoxic HSA aggregates, and the inhibitory effects are more pronounced when both of these drugs are added simultaneously.
In VivoBenserazide (5-50 mg/kg; intraperitoneal injection; male Wistar rats) treatment of 6-OHDA-lesioned rats increases exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels are significantly prolong by Benserazide dose-dependently. The AADC activity in the denervates striatal tissues shows a significant decrease by 10 mg/kg and 50 mg/kg Benserazide. Benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous L-DOPA.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM3.4048 mL17.0242 mL34.0483 mL68.0967 mL
5mM0.6810 mL3.4048 mL6.8097 mL13.6193 mL
10mM0.3405 mL1.7024 mL3.4048 mL6.8097 mL
20mM0.1702 mL0.8512 mL1.7024 mL3.4048 mL
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.